LDS/Medical Tests/Insulin, Free and Total

Insulin, Free and Total

Insulin is a protein hormone that is synthesized, stored, and secreted by the beta cells located in the islets of Langerhans in the pancreas. Insulin is responsible for regulating glucose concentrations in the blood. Failed production, release, or the presence of anti-insulin antibodies will result in persistently elevated serum blood glucose concentration (hyperglycemia) and often a diagnosis of diabetes mellitus. There are two types of diabetes mellitus: type I or insulin-dependent diabetes mellitus (IDDM), and type II or non-insulin-dependent diabetes mellitus (NIDDM). Insulin therapy is indicated for most insulin-dependent diabetes mellitus patients and many non-insulin-dependent diabetes mellitus patients.

In type I diabetes (IDDM) there is a deficiency of insulin. This can be the result of failed production of bioactive insulin including autoimmune destruction of pancreatic beta cells or the presence of autoantibodies to insulin.

Many factors can play a role in the development of Type II diabetes (NIDDM). Type II diabetes (NIDDM) can result from decreased or diminished insulin secretion due to pancreatic beta cell failure or resulting from decreased biological response to circulating insulin (insulin resistance).

Insulin levels can be useful in evaluating patients with fasting hypoglycemia, in determining insulin resistance, and in assessing abnormalities in beta cell secretory function. Insulin levels are useful in studying the pathophysiology of diabetes.

Insulin may be used, often along with glucose and C-peptide levels, to help diagnose insulinomas, and to help diagnose documented acute or chronic (fasting) hypoglycemia. Insulin and C-peptide levels may also be used to monitor endogenous (produced by the body) insulin, check for insulin resistance, and to help determine when a type 2 diabetic might need to start taking insulin injections to supplement oral medications.

  • Evaluation of patients with fasting hypoglycemia
  • Diagnostic differentiation between diabetes type I and type II
  • Evaluation of pancreatic beta-cell function
  • Evaluation of beta cell function in patients with disorders other than diabetes mellitus

Increased in:

  • Patients with insulin-resistant states such as type II diabetes
  • Glucocorticoids
  • Acromegaly
  • Liver diseases
  • Patients with surreptitious use of insulin or oral hypoglycemic agents
  • Insulinoma (pancreatic islet cell tumor)
  • Also increased in obesity

Decreased in:

  • Type I diabetes mellitus
  • Patients with impaired pituitary gland function (hypopituitarism)

2.6 - 37.6 mU/L

 

 

Electrochemiluminescence immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).

Serum (SST). 

Stability

  • Ambient: 1-3 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Serum Glucose, Insulin-to-Glucose ratio (if insulin to glucose ratio is >0.3 this is presumptive evidence of insulinoma), C-peptide (C-peptide should be used as well as serum insulin to distinguish insulinoma from surreptitious insulin use, since C-peptide will be absent with exogenous insulin use), Insulin antibodies, Insulin Like Growth Factor, Pancreatic Polypeptide, Hemoglobin A1c, Fructosamine.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Metabolism. 2011 Dec 5. [PMID: 22146092]
  • Clin Biochem. 1981 Oct;14(5):230-6. [PMID: 7037227]
  • J Clin Endocrinol Metab. 2008 Jul;93(7):2447-53. [PMID: 18460560]
  • Clin Chem Lab Med. 2003 Sep;41(9):1259-65. [PMID: 14598879]
  • Mol Cell Endocrinol. 2001 May 25;177(1-2):125-34. [PMID: 11377828]
  • Clin Lab Med. 1984 Dec;4(4):745-61. [PMID: 6391789]
  • J Clin Endocrinol Metab. 2000;85:3222. [PMID: 10999812]
  • Sacks DB. Carbohydrates. In: Burtis CA, Ashwood, ER, Tietz textbook of clinical chemistry, 2nd ed. Philadelphia:WB Saunders. 1994:935-949.